Zhu Chenglou, Liu Wenhan, Da Mingxu
The First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China.
Department of Anorectal Surgery, Gansu Provincial Hospital, Lanzhou, 730000, China.
Curr Cancer Drug Targets. 2024 Oct 1. doi: 10.2174/0115680096334160240916102105.
This study aimed to investigate the expression pattern of phosphatidylinositol 3-kinase class III (PIK3C3/vps34) in gastric cancer (GC) tissues and their juxtaposed normal counterparts and its correlation with the clinicopathological attributes and prognostic outlook of afflicted individuals.
Immunohistochemical (IHC) staining was used to ascertain the expression levels of PIK3C3/vps34 across 60 GC tissues juxtaposed with their normal counterparts. Statistical methodologies were used to scrutinize the correlation between PIK3C3/vps34 expression and clinicopathological features, along with prognostic implications for GC patients.
In GC tissues, the positive expression rate of PIK3C3/vps34 was 23.3% (14/60), which contrasted sharply with the markedly elevated rate of 66.7% (40/60) observed in adjacent tissues. The positive expression proportion of PIK3C3/vps34 within GC tissues exhibited a notable decrease than in adjacent tissues (P<0.05). The expression of PIK3C3/vps34 inverse-ly correlated with tumor size, degree of tissue differentiation, depth of tumor infiltration, and incidence of lymph node metastasis (P<0.05), whereas no significant associations were found with patient sex, age, tumor location, TNM staging, or distant metastasis (P > 0.05). As the tumor diameter increases, the degree of tissue differentiation diminishes, tumor infiltration depth intensifies, lymph node metastasis emerges, the TNM stage progresses, and PIK3C3/vps34 expression level within GC tissues declines correspondingly. Kaplan-Meier survival analysis unveiled a prolonged survival duration among GC patients exhibiting heightened PIK3C3/vps34 expression than in their counterparts with diminished expression (HR=0.66, 95% CI: 0.55-0.80), demonstrating statistical significance (P<0.05). Protein interaction analysis revealed noteworthy interactions involving PIK3C3 with Beclin 1, UVRAG, and ATG14.
PIK3C3/vps34 is downregulated in GC tissues, exerting a pivotal role in tumorigenesis, and is intimately linked with the prognostic trajectory of GC patients. It may serve as a significant biomarker for prognostic evaluation and a promising molecular therapeutic target for GC.
本研究旨在探讨Ⅲ类磷脂酰肌醇3激酶（PIK3C3/vps34）在胃癌（GC）组织及其相邻正常组织中的表达模式，以及其与患者临床病理特征和预后的相关性。
采用免疫组织化学（IHC）染色法确定60对GC组织及其正常对照组织中PIK3C3/vps34的表达水平。运用统计学方法分析PIK3C3/vps34表达与临床病理特征之间的相关性，以及对GC患者的预后影响。
在GC组织中，PIK3C3/vps34的阳性表达率为23.3%（14/60），与相邻组织中显著升高的66.7%（40/60）形成鲜明对比。GC组织中PIK3C3/vps34的阳性表达比例明显低于相邻组织（P<0.05）。PIK3C3/vps34的表达与肿瘤大小、组织分化程度、肿瘤浸润深度及淋巴结转移发生率呈负相关（P<0.05），而与患者性别、年龄、肿瘤位置、TNM分期或远处转移无显著关联（P>0.05）。随着肿瘤直径增大、组织分化程度降低、肿瘤浸润深度增加、出现淋巴结转移、TNM分期进展，GC组织中PIK3C3/vps34的表达水平相应下降。Kaplan-Meier生存分析显示，PIK3C3/vps34高表达的GC患者的生存时间长于低表达者（HR=0.66，95%CI：0.55-0.80），差异具有统计学意义（P<0.05）。蛋白质相互作用分析显示PIK3C3与Beclin 1、UVRAG和ATG14之间存在显著相互作用。
PIK3C3/vps34在GC组织中表达下调，在肿瘤发生中起关键作用，且与GC患者的预后密切相关。它可能是预后评估的重要生物标志物，也是GC有前景的分子治疗靶点。
